Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Stock Information for Aadi Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aadi Bioscience Inc.

Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update
Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.